Discgenics Announces the Appointment of Robert M. Wynalek as Chief Operating and Commercialization Officer

SALT LAKE CITY, June 26, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics), a spinal therapeutics company that is developing a proprietary disc stem cell technology to treat degenerative disc disease, announces the appointment of Robert M. Wynalek as its Chief Operating and Commercialization Officer. Discgenics' CEO Flagg Flanagan said, "we are truly excited to have Bob join us in an executive capacity in addition to his role as a Discgenics board director and investor. Bob brings to Discgenics extensive leadership expertise in Biologics, Spinal Devices and Orthopedics having served most recently as President, Domestic at orthobiologics leader Osteotech, Inc. prior to its acquisition by Medtronic, Inc. during late 2010. This combined with his experience at Medtronic, Sofamor Danek Group, and Smith & Nephew Orthopedics, will bring tremendous benefits to Discgenics as we continue to develop and commercialize our science and technology for the treatment of degenerative disc disease."

About Discgenics, Inc.

Discgenics is a privately funded Spinal therapeutics company that is utilizing tissue engineering and adult human disc stem cell technology to develop a treatment for patients debilitated by degenerative disc disease. News and other information are available at: http://www.discgenics.com.

Media Contact: Flagg Flanagan
Chief Executive Officer

SOURCE Discgenics, Inc.

Back to news